03/18/23 2:40 PMNasdaq : CNTB low floatConnect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient SymptomsConnect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the...RHEA-AIneutral
03/17/23 4:05 PMNasdaq : CNTB clinical triallow floatConnect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body RegionsConnect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that post hoc data analysis from the Phase 2 b CBP-201 global trial in moderate-to-severe atopic dermatitis showed that CBP-201 led to rapid and...RHEA-AIpositive
03/06/23 8:15 AMNasdaq : CNTB low floatConnect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual MeetingConnect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis have been accepted for presentation at the American Academy...RHEA-AIvery positive
02/06/23 8:30 AMNasdaq : CNTB conferenceslow floatConnect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom CaliforniaConnect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting, and hostingRHEA-AIneutral
12/30/22 7:30 AMNasdaq : CNTB clinical triallow floatConnect Biopharma Provides Business and Clinical Development Program UpdateCash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program Progress of ChinaRHEA-AIvery positive
12/19/22 8:00 AMNasdaq : CNTB conferenceslow floatConnect Biopharma to Present at the San Francisco Biotech Showcase in JanuaryConnect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced thatRHEA-AIneutral
12/02/22 5:00 PMNasdaq : CNTB low floatConnect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementConnect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that,RHEA-AIneutral
10/27/22 4:05 PMNasdaq : CNTB conferenceslow floatConnect Biopharma To Present at Upcoming Investor and Scientific ConferencesConnect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting and/or hostingRHEA-AIneutral
10/04/22 8:56 AMNasdaq : CNTB low floatCORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaIn a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in the "About the Trial" section, the fourth sentence should read "Stage 2 36-week maintenance period",RHEA-AIneutral
10/04/22 7:00 AMNasdaq : CNTB low floatConnect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaAll primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the IL-4Rα pathway Data support advancing the regulatory discussions with the CDE for submittingRHEA-AIneutral